Is CLSD or RYLD a better dividend investment in 2026?

CLSD currently yields 487.80% with a 5% 5-year dividend growth rate. RYLD yields 12.14% with 5% growth. The better choice depends on your goal: CLSD offers higher current income.

What is the dividend yield difference between CLSD and RYLD?

CLSD has a forward dividend yield of 487.80% ($2.00/share annually). RYLD yields 12.14% ($1.81/share annually). The yield gap is 475.66 percentage points.

Home › Compare › CLSD vs RYLD

CLSD vs RYLD: Dividend Comparison 2026

CLSD yields 487.80% · RYLD yields 12.14%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CLSD wins by $50753.85M in total portfolio value

INVESTMENT

TIME HORIZON10 years

CLSD

● Live price

487.80%

Share price

$0.41

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$50753.89M

Annual income

$36,168,404,531.85

Full CLSD calculator →

RYLD

● Live price

12.14%

Share price

$14.95

Annual div

$1.81

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.5K

Annual income

$2,587.35

Full RYLD calculator →

Portfolio growth — CLSD vs RYLD

📍 CLSD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CLSD	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CLSD + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CLSD pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLSD

Annual income on $10K today (after 15% tax)

$41,463.41/yr

After 10yr DRIP, annual income (after tax)

$30,743,143,852.07/yr

RYLD

Annual income on $10K today (after 15% tax)

$1,031.60/yr

After 10yr DRIP, annual income (after tax)

$2,199.25/yr

At 15% tax rate, CLSD beats the other by $30,743,141,652.82/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLSD + RYLD for your $10,000?

CLSD: 50%RYLD: 50%

100% RYLD50/50100% CLSD

Portfolio after 10yr

$25376.97M

Annual income

$18,084,203,559.60/yr

Blended yield

71.26%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on CLSD right now

CLSD

Analyst Ratings

Buy

Hold

Consensus: Buy

Altman Z

-48.3

Piotroski

2/9

RYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLSD buys

RYLD buys

No recent congressional trades found for CLSD or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCLSDRYLD

Forward yield	487.80% ✓	12.14%
Annual dividend / share	$2.00 ✓	$1.81
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$50753.89M ✓	$44.5K
Annual income after 10y	$36,168,404,531.85 ✓	$2,587.35
Total dividends collected	$49478.61M ✓	$18.8K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: CLSD vs RYLD ($10,000, DRIP)

Year	CLSD Portfolio	CLSD Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1← crossover	$59,480	$48,780.49	$11,914	$1,213.65	+$47.6K → CLSD
2	$334,811	$271,167.03	$14,099	$1,351.30	+$320.7K → CLSD
3	$1,784,770	$1,426,522.08	$16,580	$1,494.55	+$1.77M → CLSD
4	$9,016,553	$7,106,848.63	$19,384	$1,642.61	+$9.00M → CLSD
5	$43,202,271	$33,554,559.81	$22,535	$1,794.70	+$43.18M → CLSD
6	$196,483,123	$150,256,693.49	$26,063	$1,950.00	+$196.46M → CLSD
7	$848,895,486	$638,658,543.63	$29,995	$2,107.69	+$848.87M → CLSD
8	$3,487,095,949	$2,578,777,778.75	$34,361	$2,266.99	+$3487.06M → CLSD
9	$13,631,297,985	$9,900,105,319.66	$39,194	$2,427.12	+$13631.26M → CLSD
10	$50,753,893,375	$36,168,404,531.85	$44,525	$2,587.35	+$50753.85M → CLSD

CLSD vs RYLD: Complete Analysis 2026

CLSD — Stock

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Full CLSD Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →

📬

Get this CLSD vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLSD vs SCHD CLSD vs JEPI CLSD vs O CLSD vs KO CLSD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.